BenzingaOctober 21, 2026 at 7:08 AM NY6 Days Ago
TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $980
TD Cowen analyst Tyler Van Buren maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $960 to $980.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
